Published in Cancer Res on January 12, 2010
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer (2011) 1.21
Functional role of post-translational modifications of Sp1 in tumorigenesis. J Biomed Sci (2012) 1.09
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One (2010) 0.93
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Glutamine protects against apoptosis via downregulation of Sp3 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2010) 0.90
Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med (2013) 0.90
Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp Cell Res (2014) 0.88
Resveratrol-induced apoptosis is mediated by early growth response-1, Krüppel-like factor 4, and activating transcription factor 3. Cancer Prev Res (Phila) (2011) 0.88
Dietary fiber. Adv Nutr (2011) 0.88
Zinc sensing receptor signaling, mediated by GPR39, reduces butyrate-induced cell death in HT29 colonocytes via upregulation of clusterin. PLoS One (2012) 0.87
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. Biomolecules (2015) 0.86
Gastrin inhibits a novel, pathological colon cancer signaling pathway involving EGR1, AE2, and P-ERK. J Mol Med (Berl) (2012) 0.85
Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol (2011) 0.85
Butyrate produced by commensal bacteria potentiates phorbol esters induced AP-1 response in human intestinal epithelial cells. PLoS One (2012) 0.84
Gene expression during zombie ant biting behavior reflects the complexity underlying fungal parasitic behavioral manipulation. BMC Genomics (2015) 0.83
Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination. Cancer Cell Int (2010) 0.82
Massive human co-expression network and its medical applications. Chem Biodivers (2012) 0.82
Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A. Int J Nanomedicine (2011) 0.81
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Antioxid Redox Signal (2014) 0.80
Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis. Mol Cancer (2011) 0.80
The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis. Curr Gastroenterol Rep (2013) 0.79
Zac1 is a histone acetylation-regulated NF-κB suppressor that mediates histone deacetylase inhibitor-induced apoptosis. Cell Death Differ (2011) 0.79
Propolis augments apoptosis induced by butyrate via targeting cell survival pathways. PLoS One (2013) 0.79
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J (2014) 0.78
A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression. Elife (2016) 0.76
Butyrylated starch affects colorectal cancer markers beneficially and dose-dependently in genotoxin-treated rats. Cancer Biol Ther (2014) 0.76
Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. Br J Pharmacol (2013) 0.75
Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg Med Chem (2016) 0.75
Trefoil factor family 2 expression inhibits gastric cancer cell growth and invasion in vitro via interactions with the transcription factor Sp3. Int J Mol Med (2016) 0.75
An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases. Diseases (2015) 0.75
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell (1997) 16.79
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics (2005) 7.13
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics (2008) 6.45
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Acetylation of general transcription factors by histone acetyltransferases. Curr Biol (1997) 4.22
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci (2003) 3.67
The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J (1999) 3.58
Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol (2001) 3.34
The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol (1991) 3.08
Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene (2004) 2.96
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 2.61
Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene (2003) 2.11
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res (2003) 1.91
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther (2002) 1.88
E2F family members are differentially regulated by reversible acetylation. J Biol Chem (2000) 1.77
Signaling events for metallothionein induction. Mutat Res (2003) 1.60
HDACs and HDAC inhibitors in colon cancer. Epigenetics (2008) 1.58
Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest (1989) 1.53
Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res (2001) 1.47
A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics (2007) 1.43
TR3/Nur77 in colon cancer cell apoptosis. Cancer Res (2003) 1.39
Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res (2005) 1.32
Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res (2004) 1.31
Acetylated sp3 is a transcriptional activator. J Biol Chem (2003) 1.30
Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut (2003) 1.23
Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. Oncogene (2006) 1.11
Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer (2007) 1.08
Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ (1997) 1.05
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett (2002) 1.05
Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther (2005) 1.04
Goals for signal transduction pathways: linking up with transcriptional regulation. EMBO J (1994) 1.03
Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ (1998) 1.02
Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med (Berl) (2007) 1.01
Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J Biol Chem (2001) 0.98
Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis (2003) 0.94
Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery (2001) 0.87
Colorectal cancer in mice genetically deficient in the mucin Muc2. Science (2002) 5.08
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science (2013) 3.74
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem (2006) 3.15
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res (2009) 3.08
Neocentromeres: new insights into centromere structure, disease development, and karyotype evolution. Am J Hum Genet (2008) 2.88
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (2005) 2.05
Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 1.99
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology (2005) 1.93
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res (2003) 1.91
Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol (2004) 1.80
Kaiso-deficient mice show resistance to intestinal cancer. Mol Cell Biol (2006) 1.67
HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell (2008) 1.67
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
Bedside technique to detect misplaced subclavian vein catheter in internal jugular vein. Ann Card Anaesth (2010) 1.62
Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis (2008) 1.60
SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res (2005) 1.50
Merlin is a potent inhibitor of glioma growth. Cancer Res (2008) 1.47
c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol (2007) 1.44
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs (2009) 1.41
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther (2007) 1.40
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39
TR3/Nur77 in colon cancer cell apoptosis. Cancer Res (2003) 1.39
Intraoperative detection of a stuck bioprosthetic mitral valve leaflet causing severe mitral regurgitation. J Cardiothorac Vasc Anesth (2011) 1.38
Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A (2006) 1.38
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res (2008) 1.34
Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis (2008) 1.28
A gene expression profile that defines colon cell maturation in vitro. Cancer Res (2002) 1.27
Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J (2013) 1.26
Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet (2005) 1.26
Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res (2005) 1.26
NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology (2008) 1.24
ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle (2008) 1.21
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
EPHB4 and survival of colorectal cancer patients. Cancer Res (2006) 1.17
Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice. Am J Pathol (2005) 1.14
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs (2004) 1.12
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res (2010) 1.12
The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res (2005) 1.12
Intestinal deletion of Pofut1 in the mouse inactivates notch signaling and causes enterocolitis. Gastroenterology (2008) 1.12
Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer (2011) 1.08
Targeted inactivation of p27kip1 is sufficient for large and small intestinal tumorigenesis in the mouse, which can be augmented by a Western-style high-risk diet. Cancer Res (2003) 1.07
LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis (2013) 1.06
Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol (2008) 1.06
Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol (2011) 1.05
p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res (2005) 1.05
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res (2009) 1.04
Proteomic changes during intestinal cell maturation in vivo. J Proteomics (2008) 1.02